# Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma

> **NCT07748988** · PHASE1 · RECRUITING · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 12 (estimated)

## Conditions studied

- Refractory Clear Cell Renal Cell Carcinoma
- Metastatic Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** casdatifan

## Key facts

- **NCT ID:** NCT07748988
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-21
- **Primary completion:** 2030-07-01
- **Final completion:** 2031-01-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07748988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07748988, "Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07748988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*